ADAPTIMMUNE THERAPEUTICS PLC (NASDAQ:ADAP) Files An 8-K Results of Operations and Financial Condition

ME Staff 8-k
-
0
ADAPTIMMUNE THERAPEUTICS PLC (NASDAQ:ADAP) Files An 8-K Results of Operations and Financial Condition

ADAPTIMMUNE THERAPEUTICS PLC (NASDAQ:ADAP) Files An 8-K Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Conditions

On August2, 2018, Adaptimmune Therapeutics plc (the “Company”) issued a press release announcing its financial results for the second quarter ended June30, 2018 and providing a business update. The text of the press release is attached as Exhibit99.1 and is incorporated by reference herein.

The information contained in Item 2.02 of this Form8-K, including the attached Exhibit99.1, shall not be deemed “filed” for purposes of Section18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by the Company by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.


Adaptimmune Therapeutics PLC Exhibit
EX-99.1 2 a18-18121_1ex99d1.htm EX-99.1 Exhibit 99.1     Adaptimmune Reports Second Quarter 2018 Financial Results and Business Update   – Dosing patients in both MAGE-A10 pilot studies in third cohort with range of one to six billion cells –   – NY-ESO program transitioned to GSK allows clinical focus on wholly owned assets –   – Guidance confirmed,…
To view the full exhibit click here

About ADAPTIMMUNE THERAPEUTICS PLC (NASDAQ:ADAP)

Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company. The Company is focused on cancer immunotherapy products based on its T-cell receptor (TCR) platform. The Company has developed a platform that enables it to identify cancer targets in the form of peptides, which are short sequences of amino acids, find and genetically engineer TCRs, and produce TCR therapeutic candidates for administration to patients. The Company engineers TCRs to increase their affinity to cancer-specific peptides, including its lead target peptides, NY-ESO-1 and MAGE-A10, in order to target and then destroy cancer cells in patients. The Company’s TCR therapeutic candidates are able to target intracellular, as well as extracellular cancer antigens. The TCRs consist of approximately two associated protein chains: the alpha and beta chains. Each of the chains has approximately two regions: a variable region and a constant region.